Fig. 4

Prognostic relevance of ESRP1 in all cancers (n = 9818), ERG-negative cancers (n = 4344), and ERG-positive cancers (n = 3585), of ESRP2 in all cancers (n = 9818), ERG-negative cancers (n = 4666), and ERG-positive cancers (n = 3791), and combined ESRP1/ESRP2 status in all cancers (n = 9414). Survival curves were calculated according to Kaplan-Meier. The Log-Rank test was applied to detect significant differences between groups